Is Amphastar Pharmaceuticals, Inc. (AMPH) the Best Pharma Stock to Buy for Long Term Growth?
AI replacing animal experiments? A message from the FDA has left "monkey breeders" feeling devastated, and experts state that "we are still far from the stage of implementation."
① The news that the USA FDA has publicly stated it will gradually replace animal testing requirements has led to an increase in the stock prices of AI pharmaceutical companies, impacting traditional drug evaluation CRO companies; ② Some believe this action represents a trend in Industry development. However, others believe that it is far from being implementable.
Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Needham Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating
Needham Reiterates Hold on Amphastar Pharmato Hold
We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Stay On Top Of Its Debt
Amphastar Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
Insider Sale: Director at $AMPH Sells 500 Shares
International Medication Systems, Ltd. Receives FDA's Drug Shortage Assistance Award
Hospital Stocks Are Ready to Rebound, Deutsche Bank Says
Proposed Medicaid Cuts Would Devastate Local Economies: Report -- Barrons.com
Amphastar Pharmaceuticals Is Maintained at Neutral by Piper Sandler
Amphastar Pharma Analyst Ratings
Piper Sandler Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating, Cuts Target Price to $32
The tariff war between the US and Europe is escalating, and Trump's 'tariff big stick' is making the pharmaceutical industry tremble.
Pharmaceutical companies are urging the Trump administration and EU officials to exclude Medical products from the escalation of the trade war.
New York Manufacturing Hits Low, Inflation Fears Rise
Q4 Earnings Highs And Lows: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Generic Pharmaceuticals Stocks
Amphastar Pharmaceuticals to Present at the Barclays 27th Annual Global Healthcare Conference
Amphastar Pharmaceuticals | 10-K: FY2024 Annual Report
A Quick Look at Today's Ratings for Amphastar Pharmaceuticals(AMPH.US), With a Forecast Between $36 to $40